Although Not Improving DFS, Adjuvant Avelumab May Potentially Reduce the Risk of Death in Patients with High-Risk TNBC By Ogkologos - September 9, 2025 634 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the A-BRAVE study Source RELATED ARTICLESMORE FROM AUTHOR Mezigdomide-Carfilzomib-Dexamethasone Prolongs PFS Compared with Carfilzomib-Dexamethasone at First Relapse in Patients with Relapsed Or Refractory Multiple Myeloma FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer Systemic Aging Associated with a Higher Risk of Early-Onset Solid Cancers MOST POPULAR FDA Approves Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma March 25, 2022 FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer... June 10, 2026 Self Destruction September 8, 2022 ΜΥΘΟΙ ΚΑΙ ΑΛΗΘΕΙΕΣ November 26, 2018 Load more HOT NEWS New Combination of Old Drugs Improves Survival in Patients with Prostate... How I Found a Meaningful Career After Cancer FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer... An Important Part of Cancer Caregiving That’s Often Overlooked and How...
